Protocol Ledger

NCT07507760 · Phase II · RECRUITING

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

Interventional Phase II clinical trial protocol NCT07507760 sponsored by PETHEMA Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-12 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07507760
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07507760
Protocol FieldVerified Registry Value
NCT IdentifierNCT07507760
Consolidated Lead SponsorPETHEMA Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2026-06-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07507760
Hospital Research SiteLocationSite Profile
Hospital Universitario Virgen del RocíoSeville, SpainOpen Hospital Dossier ->
Hospital Universitari I Politècnic La FeValencia, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI